How should antibiotic therapy be de-escalated in the setting of culture results?

• A. Continue broad-spectrum therapy until culture results show improvement.
• B. Narrow spectrum to the identified pathogen, discontinue extraneous agents.
• C. Narrow spectrum to the identified pathogen, discontinue extraneous agents, and switch from IV to oral when feasible.
• D. Stop all antibiotics immediately.

Answer: (C)

When culture results are available, tailor therapy to the identified pathogen and its susceptibilities, remove any unnecessary drugs, and switch from IV to oral therapy when the patient is able to take oral medications and the organism is susceptible to an effective oral agent. This de-escalation approach is central to antimicrobial stewardship: it reduces exposure to broad-spectrum agents that disrupt normal flora and drive resistance, lowers the risk of adverse effects, and often allows earlier discharge or outpatient management.

Narrowing to a drug that specifically targets the pathogen ensures the infection is treated effectively while avoiding the collateral damage of broad coverage. Discontinuing extraneous agents prevents redundant or unnecessary antibiotics from continuing. Switching from IV to oral when feasible maintains effective treatment while improving convenience, reducing IV-related complications, and supporting patient mobility and resource use.

The other approaches miss important benefits: continuing broad-spectrum therapy beyond the point where culture data exist sustains unnecessary risk and resistance pressure; stopping antibiotics abruptly can leave the infection undertreated; and narrowing without moving to an oral form can unnecessarily prolong hospitalization and IV therapy even when an oral option would be suitable.